PASSAMONTI, FRANCESCO
PASSAMONTI, FRANCESCO
DIPARTIMENTO DI MEDICINA MOLECOLARE
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
2008-01-01 Passamonti, Francesco; Rumi, Elisa; Caramella, M; Elena, Chiara; Arcaini, Luca; Boveri, E; Del Curto, C; Pietra, D; Vanelli, L; Bernasconi, Paolo; Pascutto, C; Cazzola, Mario; Morra, E; Lazzarino, Mario
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
2010-01-01 Passamonti, Francesco; Cervantes, F; Vannucchi, Am; Morra, E; Rumi, Elisa; Pereira, A; Guglielmelli, P; Pungolino, E; Caramella, M; Maffioli, M; Pascutto, C; Lazzarino, Mario; Cazzola, Mario; Tefferi, A.
A gain-of-function mutation of JAK2 in myeloproliferative disorders
2005-01-01 Kralovics, R; Passamonti, Francesco; Buser, As; Teo, Ss; Tiedt, R; Passweg, Jr; Tichelli, A; Cazzola, Mario; Skoda, Rc
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients
2007-01-01 Brazzelli, V; Prestinari, F; Barbagallo, T; Rona, Claudia; Orlandi, E; Passamonti, F; Locatelli, F; Zecca, M; Villani, S; Borroni, G.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
2014-01-01 Verstovsek, S; Passamonti, Francesco; Rambaldi, A; Barosi, G; Rosen, Pj; Rumi, Elisa; Gattoni, E; Pieri, L; Guglielmelli, P; Elena, Chiara; He, S; Contel, N; Mookerjee, B; Sandor, V; Cazzola, Mario; Kantarjian, Hm; Barbui, T; Vannucchi, A. M.
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
2010-01-01 Passamonti, Francesco; Rumi, Elisa; Pietra, D; Elena, Chiara; Boveri, E; Arcaini, Luca; Roncoroni, E; Astori, C; Merli, M; Boggi, S; Pascutto, C; Lazzarino, Mario; Cazzola, Mario
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
2009-01-01 Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, H; Kiladijan, Jj; Lengfelder, E; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T.
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA
2002-01-01 Bernasconi, Paolo; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C.
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
2005-01-01 Kralovics, R; Teo, Ss; Buser, As; Brutsche, M; Tiedt, R; Tichelli, A; Passamonti, Francesco; Pietra, D; Cazzola, Mario; Skoda, Rc
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry.
2010-01-01 Merli, Michele; Arcaini, Luca; Boveri, E; Rattotti, Sara; Picone, C; Passamonti, Francesco; Tenore, A; Sozzani, L; Lucioni, Marco; Varettoni, M; Rizzi, Silvia; Morello, L; Ferretti, V; Pascutto, C; Paulli, Marco; Lazzarino, Mario
Balancing efficacy and safety of JAK inhibitors in myelofibrosis
2014-01-01 Passamonti, Francesco
Blast phase of essential thrombocythemia: A single center study.
2009-01-01 Passamonti, Francesco; Rumi, Elisa; Arcaini, Luca; Elena, Chiara; Castagnola, C; Zappasodi, P; Bernasconi, Paolo; Pietra, D; Pascutto, C; Cazzola, Mario; Lazzarino, Mario
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis.
2009-01-01 Rumi, Elisa; Passamonti, Francesco; Pagano, L; Ammirabile, M; Arcaini, Luca; Elena, Chiara; Flagiello, A; Tedesco, R; Vercellati, C; Marcello, Ap; Pietra, D; Moratti, Remigio; Cazzola, Mario; Lazzarino, Mario
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.
2012-01-01 Carobbio, A; Finazzi, G; Thiele, J; Kvasnicka, Hm; Passamonti, Francesco; Rumi, Elisa; Ruggeri, M; Rodeghiero, F; Luigia Randi, M; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer Ausch, V; Gangat, N; Rambaldi, A; Tefferi, A; Barbui, T.
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
2014-01-01 A., Tefferi; T. L., Lasho; C. M., Finke; R. A., Knudson; R., Ketterling; C. H., Hanson; M., Maffioli; D., Caramazza; Passamonti, Francesco; A., Pardanani
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
2020-01-01 Passamonti, F.; Cattaneo, C.; Arcaini, L.; Bruna, R.; Cavo, M.; Merli, F.; Angelucci, E.; Krampera, M.; Cairoli, R.; Della Porta, M. G.; Fracchiolla, N.; Ladetto, M.; Gambacorti Passerini, C.; Salvini, M.; Marchetti, M.; Lemoli, R.; Molteni, A.; Busca, A.; Cuneo, A.; Romano, A.; Giuliani, N.; Galimberti, S.; Corso, A.; Morotti, A.; Falini, B.; Billio, A.; Gherlinzoni, F.; Visani, G.; Tisi, M. C.; Tafuri, A.; Tosi, P.; Lanza, F.; Massaia, M.; Turrini, M.; Ferrara, F.; Gurrieri, C.; Vallisa, D.; Martelli, M.; Derenzini, E.; Guarini, A.; Conconi, A.; Cuccaro, A.; Cudillo, L.; Russo, D.; Ciambelli, F.; Scattolin, A. M.; Luppi, M.; Selleri, C.; Ortu La Barbera, E.; Ferrandina, C.; Di Renzo, N.; Olivieri, A.; Bocchia, M.; Gentile, M.; Marchesi, F.; Musto, P.; Federici, A. B.; Candoni, A.; Venditti, A.; Fava, C.; Pinto, A.; Galieni, P.; Rigacci, L.; Armiento, D.; Pane, F.; Oberti, M.; Zappasodi, P.; Visco, C.; Franchi, M.; Grossi, P. A.; Bertu, L.; Corrao, G.; Pagano, L.; Corradini, P.
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
2014-01-01 G., Barosi; A., Tefferi; C., Besses; G., Birgegard; F., Cervantes; G., Finazzi; H., Gisslinger; M., Griesshammer; C., Harrison; R., Hehlmann; S., Hermouet; J. J., Kiladjian; N., Kröger; R., Mesa; M. F., Mc Mullin; A., Pardanani; Passamonti, Francesco; J., Samuelsson; A. M., Vannucchi; A., Reiter; R. T., Silver; S., Verstovsek; G., Tognoni; T., Barbui
Clinical Predictors of Outcome in MPN.
2012-01-01 Passamonti, Francesco; Maffioli, M; Merli, M; Ferrario, A; Caramazza, D.
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome
2009-01-01 DELLA PORTA, MATTEO GIOVANNI; Malcovati, Luca; Boveri, E; Travaglino, E; Pietra, D; Pascutto, C; Passamonti, Francesco; Invernizzi, Rosangela; Castello, Alessandro; Magrini, Umberto; Lazzarino, Mario; Cazzola, Mario
Clinical relevance of JAK2 (V617F) mutant allele burden
2009-01-01 Passamonti, Francesco; Rumi, Elisa
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis | 1-gen-2008 | Passamonti, Francesco; Rumi, Elisa; Caramella, M; Elena, Chiara; Arcaini, Luca; Boveri, E; Del Curto, C; Pietra, D; Vanelli, L; Bernasconi, Paolo; Pascutto, C; Cazzola, Mario; Morra, E; Lazzarino, Mario | |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) | 1-gen-2010 | Passamonti, Francesco; Cervantes, F; Vannucchi, Am; Morra, E; Rumi, Elisa; Pereira, A; Guglielmelli, P; Pungolino, E; Caramella, M; Maffioli, M; Pascutto, C; Lazzarino, Mario; Cazzola, Mario; Tefferi, A. | |
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | 1-gen-2005 | Kralovics, R; Passamonti, Francesco; Buser, As; Teo, Ss; Tiedt, R; Passweg, Jr; Tichelli, A; Cazzola, Mario; Skoda, Rc | |
| A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients | 1-gen-2007 | Brazzelli, V; Prestinari, F; Barbagallo, T; Rona, Claudia; Orlandi, E; Passamonti, F; Locatelli, F; Zecca, M; Villani, S; Borroni, G. | |
| A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea | 1-gen-2014 | Verstovsek, S; Passamonti, Francesco; Rambaldi, A; Barosi, G; Rosen, Pj; Rumi, Elisa; Gattoni, E; Pieri, L; Guglielmelli, P; Elena, Chiara; He, S; Contel, N; Mookerjee, B; Sandor, V; Cazzola, Mario; Kantarjian, Hm; Barbui, T; Vannucchi, A. M. | |
| A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. | 1-gen-2010 | Passamonti, Francesco; Rumi, Elisa; Pietra, D; Elena, Chiara; Boveri, E; Arcaini, Luca; Roncoroni, E; Astori, C; Merli, M; Boggi, S; Pascutto, C; Lazzarino, Mario; Cazzola, Mario | |
| A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | 1-gen-2009 | Barosi, G; Birgegard, G; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, H; Kiladijan, Jj; Lengfelder, E; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Reilly, Jt; Vannucchi, Am; Barbui, T. | |
| ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA | 1-gen-2002 | Bernasconi, Paolo; Boni, M.; Cavigliano, P. M. .; Calatroni, S.; Brusamolino, E.; Passamonti, Francesco; Pistorio, A.; Giardini, I.; Rocca, B.; Caresana, M.; Lazzarino, M.; Brernasconi, C. | |
| Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 | 1-gen-2005 | Kralovics, R; Teo, Ss; Buser, As; Brutsche, M; Tiedt, R; Tichelli, A; Passamonti, Francesco; Pietra, D; Cazzola, Mario; Skoda, Rc | |
| Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. | 1-gen-2010 | Merli, Michele; Arcaini, Luca; Boveri, E; Rattotti, Sara; Picone, C; Passamonti, Francesco; Tenore, A; Sozzani, L; Lucioni, Marco; Varettoni, M; Rizzi, Silvia; Morello, L; Ferretti, V; Pascutto, C; Paulli, Marco; Lazzarino, Mario | |
| Balancing efficacy and safety of JAK inhibitors in myelofibrosis | 1-gen-2014 | Passamonti, Francesco | |
| Blast phase of essential thrombocythemia: A single center study. | 1-gen-2009 | Passamonti, Francesco; Rumi, Elisa; Arcaini, Luca; Elena, Chiara; Castagnola, C; Zappasodi, P; Bernasconi, Paolo; Pietra, D; Pascutto, C; Cazzola, Mario; Lazzarino, Mario | |
| Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. | 1-gen-2009 | Rumi, Elisa; Passamonti, Francesco; Pagano, L; Ammirabile, M; Arcaini, Luca; Elena, Chiara; Flagiello, A; Tedesco, R; Vercellati, C; Marcello, Ap; Pietra, D; Moratti, Remigio; Cazzola, Mario; Lazzarino, Mario | |
| Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. | 1-gen-2012 | Carobbio, A; Finazzi, G; Thiele, J; Kvasnicka, Hm; Passamonti, Francesco; Rumi, Elisa; Ruggeri, M; Rodeghiero, F; Luigia Randi, M; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer Ausch, V; Gangat, N; Rambaldi, A; Tefferi, A; Barbui, T. | |
| CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | 1-gen-2014 | A., Tefferi; T. L., Lasho; C. M., Finke; R. A., Knudson; R., Ketterling; C. H., Hanson; M., Maffioli; D., Caramazza; Passamonti, Francesco; A., Pardanani | |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study | 1-gen-2020 | Passamonti, F.; Cattaneo, C.; Arcaini, L.; Bruna, R.; Cavo, M.; Merli, F.; Angelucci, E.; Krampera, M.; Cairoli, R.; Della Porta, M. G.; Fracchiolla, N.; Ladetto, M.; Gambacorti Passerini, C.; Salvini, M.; Marchetti, M.; Lemoli, R.; Molteni, A.; Busca, A.; Cuneo, A.; Romano, A.; Giuliani, N.; Galimberti, S.; Corso, A.; Morotti, A.; Falini, B.; Billio, A.; Gherlinzoni, F.; Visani, G.; Tisi, M. C.; Tafuri, A.; Tosi, P.; Lanza, F.; Massaia, M.; Turrini, M.; Ferrara, F.; Gurrieri, C.; Vallisa, D.; Martelli, M.; Derenzini, E.; Guarini, A.; Conconi, A.; Cuccaro, A.; Cudillo, L.; Russo, D.; Ciambelli, F.; Scattolin, A. M.; Luppi, M.; Selleri, C.; Ortu La Barbera, E.; Ferrandina, C.; Di Renzo, N.; Olivieri, A.; Bocchia, M.; Gentile, M.; Marchesi, F.; Musto, P.; Federici, A. B.; Candoni, A.; Venditti, A.; Fava, C.; Pinto, A.; Galieni, P.; Rigacci, L.; Armiento, D.; Pane, F.; Oberti, M.; Zappasodi, P.; Visco, C.; Franchi, M.; Grossi, P. A.; Bertu, L.; Corrao, G.; Pagano, L.; Corradini, P. | |
| Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) | 1-gen-2014 | G., Barosi; A., Tefferi; C., Besses; G., Birgegard; F., Cervantes; G., Finazzi; H., Gisslinger; M., Griesshammer; C., Harrison; R., Hehlmann; S., Hermouet; J. J., Kiladjian; N., Kröger; R., Mesa; M. F., Mc Mullin; A., Pardanani; Passamonti, Francesco; J., Samuelsson; A. M., Vannucchi; A., Reiter; R. T., Silver; S., Verstovsek; G., Tognoni; T., Barbui | |
| Clinical Predictors of Outcome in MPN. | 1-gen-2012 | Passamonti, Francesco; Maffioli, M; Merli, M; Ferrario, A; Caramazza, D. | |
| Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome | 1-gen-2009 | DELLA PORTA, MATTEO GIOVANNI; Malcovati, Luca; Boveri, E; Travaglino, E; Pietra, D; Pascutto, C; Passamonti, Francesco; Invernizzi, Rosangela; Castello, Alessandro; Magrini, Umberto; Lazzarino, Mario; Cazzola, Mario | |
| Clinical relevance of JAK2 (V617F) mutant allele burden | 1-gen-2009 | Passamonti, Francesco; Rumi, Elisa |